A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

Inclusion Criteria: * Must be able to understand a written informed consent, which must be obtained prior to initiation of study procedures. * Must be willing and able to comply with all study requirements Aged 18 to 55 years inclusive at the time of signing informed consent. * Must agree to use an adequate method of contraception (as defined in Section 9.4. * Healthy males or non-pregnant, non-lactating, healthy females. * Body mass index of 18.0 to 32.0 kg/m2 as measured at screening. * Weight ≥50 kg at screening. Exclusion Criteria: * Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients. * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active. * Significant serious skin disease, including rash, food allergy, eczema, psoriasis, or urticaria. * History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease (except cholecystectomy), neurological or psychiatric disorder, as judged by the investigator. * Have poor venous access that limits phlebotomy. * Clinically significant abnormal clinical chemistry, hematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1). Participants with Gilbert's Syndrome are allowed. * Has ALT or AST \>1.5 × ULN; Total bilirubin \>1.5 × ULN (for participants with known Gilbert's syndrome these criteria only apply if the tot…